2026.02.13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 投行杰富瑞在一份致客户的报告中表示，她可能不会出现在很多CEO潜在继任者的名单中，她在默克的 业绩没有达到前任高管的水平。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲 ...

2026.02. 13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市场 可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和加 拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前，加 之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 开发新药已被证明是赛诺菲最大的难题 ...

即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前， 加之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 不过葛丽鹤在默克任职期间，该公司在新药开发方面遭遇了许多挫折，仅三款新药进入市场。此外，尽 管她在不同领域有着广泛的经验，但市 ...

Core Viewpoint - Ganli Pharmaceutical (603087) announced the approval of clinical trials for its investigational drug GLR1044 injection by the National Medical Products Administration, marking a significant step in its development pipeline [1] Group 1: Company Developments - Ganli Pharmaceutical's wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., received the clinical trial approval notice for GLR1044 injection [1] - GLR1044 injection is a biosimilar to Dupixent (dupilumab), aimed at treating moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription therapies [1]

Core Viewpoint - Ganli Pharmaceutical (603087.SH) has received approval from the National Medical Products Administration for its investigational drug GLR1044 injection, a biosimilar to Dupilumab, aimed at treating moderate to severe atopic dermatitis in adults who have inadequate control with topical prescription medications [1] Group 1 - Ganli Pharmaceutical's wholly-owned subsidiary, Ganli Pharmaceutical Shandong Co., Ltd., received the clinical trial approval notice for GLR1044 injection [1] - The acceptance number for the approval is CXSL2500849, and the notice number is 2025LP03316 [1] - GLR1044 injection is a biosimilar to Dupilumab, which is used for treating adults with moderate to severe atopic dermatitis [1]

Core Insights - The eighth China International Import Expo (CIIE) showcased significant developments in the pharmaceutical and health sectors, with JD Health forming strategic partnerships with various international brands to enhance health management services [1][3][4] Group 1: Strategic Collaborations - JD Health has established or deepened collaborations with major pharmaceutical and healthcare brands such as Eli Lilly, Novo Nordisk, Bayer, and AstraZeneca, focusing on chronic disease management and women's health [1] - The company has successfully launched new products on its platform, including innovative drugs and nutritional supplements, leveraging its extensive user base and data analytics capabilities to enhance market reach [3][4] Group 2: Supply Chain and Digital Capabilities - JD Health's "super pharmaceutical supply chain" supports efficient distribution and quality assurance of imported products, while also providing professional medical consultations through online and offline channels [1] - The rapid launch of new drugs, such as the targeted therapy for lung cancer, demonstrates JD Health's robust supply chain and digital capabilities, allowing for quick market entry and patient access [3] Group 3: Chronic Disease Management - Chronic diseases pose a significant health threat in China, with over 80% of deaths attributed to major chronic conditions, prompting a national strategy for chronic disease management [6] - JD Health's collaboration with AstraZeneca focuses on managing chronic diseases, providing patients with accessible home health management solutions [6][7] Group 4: AI and Technology Integration - The integration of AI technology in chronic disease management is a key focus, with JD Health collaborating with companies like Omron and Abbott to enhance health data connectivity and create a comprehensive smart health management ecosystem [8] - JD Health has developed various AI-driven services, including virtual doctors and nutritionists, to support patient care and health monitoring [7][8] Group 5: Ecosystem Development - The CIIE has evolved into a hub for global health ecosystem collaboration, with JD Health facilitating a shift from product-focused interactions to comprehensive value chain partnerships [10][11] - By offering a unified platform for pharmaceutical companies, JD Health reduces the complexity and costs associated with market entry, enabling efficient access to both online and offline markets [11]

Core Insights - The 8th China International Import Expo (CIIE) serves as a crucial platform for global high-quality products and advanced technologies entering the Chinese market, particularly driving innovation in the pharmaceutical and healthcare sectors [1] - Sanofi showcased its innovative product Dupixent (dupilumab), which has received recognition for its potential in treating chronic rhinosinusitis with nasal polyps and bullous pemphigoid, highlighting its breakthroughs in expanding the immune health ecosystem [1][2] - Dupixent has been approved for seven indications in China, marking significant milestones in its treatment landscape, including the recent introduction of a new indication for chronic rhinosinusitis with nasal polyps [2][7] Industry Developments - The approval of Dupixent for chronic rhinosinusitis with nasal polyps represents a critical advancement in addressing a condition that severely impacts patients' quality of life, with high recurrence rates post-surgery [2][3] - The drug is the first biologic approved for both adults and adolescents with this condition, targeting the core mechanism of type 2 inflammation [3] - The incidence of chronic rhinosinusitis with nasal polyps has been rising over the past 25 years, with a significant portion of patients also suffering from comorbidities like asthma and allergic rhinitis [3][8] Market Impact - Dupixent's rapid approval and integration into the Chinese healthcare system demonstrate a "China speed" in bringing innovative treatments to market, significantly reducing patient burden [5][6] - The drug's expansion into respiratory diseases is timely, given the severe public health challenges posed by chronic respiratory conditions in China, including a high prevalence of COPD and asthma [5][6] - The introduction of a new pre-filled injection pen for Dupixent enhances patient convenience and self-management, aligning with the growing demand for accessible chronic disease treatments [6] Future Outlook - Sanofi aims to continue expanding Dupixent's indications in China, focusing on immune, rare diseases, and oncology, with a commitment to addressing the needs of patients suffering from type 2 inflammatory diseases [7][9] - The company is actively participating in initiatives to shift treatment paradigms from symptomatic management to addressing underlying causes of diseases, fostering a collaborative healthcare ecosystem [9] - The ongoing rise in the incidence of type 2 inflammatory diseases necessitates innovative solutions, with Dupixent positioned as a key player in this therapeutic landscape [8][9]

Core Viewpoint - Hunan Maijizhi Biotechnology Co., Ltd. (Maijizhi) has submitted an IPO application to the Hong Kong Stock Exchange, focusing on the development of innovative biopharmaceuticals for allergic and autoimmune diseases, with a strong pipeline of eight candidate products [1][3]. Company Overview - Maijizhi is a biopharmaceutical company in the clinical registration stage, established in 2016, with a focus on discovering, developing, and commercializing innovative biopharmaceuticals [1]. - The company has developed a robust pipeline consisting of eight innovative candidate products, including core products MG-K10, MG-014, and MG-013 [1][3]. Product Focus - The core product MG-K10 is a long-acting anti-IL-4Rα antibody, currently undergoing clinical trials for eight indications, including atopic dermatitis and asthma [3][7]. - MG-K10 is expected to redefine care standards due to its superior safety profile compared to existing therapies, with a lower incidence of adverse events [3][7]. - The product is the only long-acting anti-IL-4Rα candidate antibody verified through Phase III clinical research as of May 2025 [3]. Market Potential - The global market for allergic disease medications was valued at $61.8 billion in 2023 and is projected to grow to $122.2 billion by 2032, with a CAGR of 7.9% [4]. - In China, the market for allergic disease medications is expected to grow from $7.2 billion in 2023 to $31 billion by 2032, with a CAGR of 17.5% [4]. Competitive Landscape - MG-K10 directly competes with Sanofi/Regenron's Dupilumab, which achieved global sales of €11.7 billion in 2023, with a market size of nearly ¥2 billion in China [3][7]. - The treatment landscape for atopic dermatitis and asthma is currently limited, with only two approved treatments in China for atopic dermatitis and 46 biologics in clinical stages for asthma globally [6]. Financial Overview - Maijizhi's revenue for 2023 was ¥8.72 million, with projected revenues of ¥0 for 2024 and 2025, indicating reliance on third-party R&D service income [8][9]. - The company recorded net losses of ¥2.53 billion in 2023, ¥1.78 billion in 2024, and ¥270 million in the first quarter of 2025, highlighting the financial challenges faced during the R&D phase [8][9]. Commercialization Strategy - The company has signed an exclusive commercialization agreement with Kangzhe Pharmaceutical Group for MG-K10, allowing joint development in China and Singapore [8]. - The IPO proceeds will allocate ¥800 million for the industrialization of MG-K10 and ¥400 million for pipeline R&D [8]. Future Outlook - The NDA application for MG-K10 is expected to be submitted in late 2025, which will be crucial for overcoming commercialization challenges faced by domestic innovative drugs [10]. - The long-term commercial viability of MG-K10 will depend on expanding indications and market education efforts [10].